Bone – based image guided group (BB) N = 89 | Fiducial – based image guided group (FB) N = 91 | |||
---|---|---|---|---|
GI | Number (%) | GI | Number (%) | p |
Acute: during treatment and the first 3 months of follow-up | 89 (100%) | Acute: during treatment and the first 3 months of follow-up | 91 (100%) | 0.29 |
G0 | 26 (29.2%) | G0 | 40 (43.9%) | |
G1 | 38 (42.7%) | G1 | 32 (35.2%) | |
G2 | 24 (27.0%) | G2 | 18 (19.8%) | |
G3 | 1 (1.1%) | G3 | 1 (1.1%) | |
Late: after the third month of follow-up | 89 (100%) | Late: after the third month of follow-up | 88 (96.7%) | 0.90 |
G0 | 51 (57.3%) | G0 | 53 (60.2%) | |
G1 | 26 (29.2%) | G1 | 20 (22.8%) | |
G2 | 9 (10.1%) | G2 | 11 (12.5%) | |
G3 | 3 (3.4%) | G3 | 4 (4.5%) | |
GU | Number (%) | GU | Number (%) | p |
Acute: during treatment and the first 3 months of follow-up | 89 (100%) | Acute: during treatment and the first 3 months of follow-up | 91 (100%) | 0.33 |
G0 | 18 (20.2%) | G0 | 22 (24.2%) | |
G1 | 32 (36.0%) | G1 | 27 (29.7%) | |
G2 | 34 (38.2%) | G2 | 41 (45.0%) | |
G3 | 5 (5.6%) | G3 | 1 (1.1%) | |
Late: after the third month of follow-up | 89 (100%) | Late: after the third month of follow-up | 88 (96.7%) | 0.12 |
G0 | 62 (69.7%) | G0 | 50 (56.8%) | |
G1 | 16 (18.0%) | G1 | 27 (30.7%) | |
G2 | 10 (11.2%) | G2 | 10 (11.4%) | |
G3 | 1 (1.1%) | G3 | 1 (1.1%) |